CASE STUDY: ADVANCING THERAPEUTICS FOR MYELOMA Oncopeptides is a clinical stage company that is developing a molecule for oncology indications. The molecule, which originated at Uppsala University, Sweden and the Karolinska Institute, is focused on multiple myeloma as a first indication. Myeloma is a very individual cancer, both in terms of what symptoms and complications patients can have and in the way they respond to treatment. Improvements made to treatment over the last decade have meant that survival rates are increasing, however there is still no cure and there remains a significant need for more efficacious and tolerable therapies. To this end, Oncopeptides, a small team of 25, based in Sweden and the United States needed an experienced partner to help take its promising mol

Join for free to read